Witness Name: Jayne Warner
Statement No. WITN7509001
Exhibits: WITN7509002-018
Dated: 14th August 2020

**INFECTED BLOOD INQUIRY**

---

**EXHIBIT WITN7509017**

---

Document 16

BLOOD PRODUCTS LABORATORY, DAGGER LANE, ELSTREE, HERTS., WD6 3BX. Tel: 01-953 6191

**Clinical response to heated factor VIII concentrate**

**Part 1. Efficacy of factor VIII infusion**

Batch HLH 3266

Patient's surname: First dose (index date):

Forename(s): Haemophilia Centre

d.o.b. Case No. 4780. First dose 5 vials = iu f.VIII

Last treated May 85 using B.P.L. (product) HL 3212. (batch)

Previous history of hepatitis

Reason for current treatment Suspect Bleed into Knee

Use the table below to record data on the efficacy of successive infusions of this batch, and Part 2 (overleaf) to record viral follow-up data with reference to the first infusion.

If subsequent treatment with another batch of this product is necessar complete Part 1 of the follow-up form relating to the second batch, but contin viral follow-up on Part 2 (overleaf) of this first batch infused.

If subsequent treatment with any other type of concentrate, cryoprecipitate or plasma is necessary, give particulars in the Remarks table below, but continue viral follow-up on Part 2 (overleaf) of the first batch infused.

Patient's mean weight 82kg. Mean resting level of factor VIII .

| Date of infusion | Hour of infusion | F.VIII iu in dose | Sampling times Pre | Sampling times Post | F.VIII levels Pre | F.VIII levels Post | Rise % | Remarks No. |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Remarks

| No. | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |

Return the photocopy of this page to Dr. T.J. Snape, BPL, as soon as the presen course of treatment is completed. Continue viral follow-up on Part 2 overleaf.

Part 2. Viral follow-up.

First dose (index date) [ ] Batch [ ]

Patient's name Case No. Haemophilia Centre

Please summarise data on possible virus transmission on the tables and photocopy the partially completed page to Dr. T.J. Snape, BPL, at 8, 24 and 52 weeks after the first dose with this batch, even if you have recorded further treatment with a different therapeutic material in Part 1 and Part 2.

| Test enquiry | Pre | Week 1 | Week 2 | Week 4 | Week 6 | Week 8 |
|---|---|---|---|---|---|---|
| Date | | | | | | |
| Bilirubin | | | | | | |
| AST/ALT (delete one) | | | | | | |
| Alk. phos. | | | | | | |
| HBsAg | | | | | | |
| Anti-HBs | | | | | | |
| Anti-HTLV III | | | | | | |
| Remarks/Note no. | | | | | | |

| Test enquiry | Week 10 | Week 12 | Week 16 | Week 20 | Week 24 |
|---|---|---|---|---|---|
| Date | | | | | |
| Bilirubin | | | | | |
| AST/ALT (delete one) | | | | | |
| Alk. phos. | | | | | |
| HBsAg | | | | | |
| Anti-HBs | | | | | |
| Anti-HTLV III | | | | | |
| Remarks/Note no. | | | | | |

| Test enquiry | Week 28 | Week 32 | Week 40 | Week 52 | |
|---|---|---|---|---|---|
| Date | | | | | |
| Bilirubin | | | | | |
| AST/ALT (delete one) | | | | | |
| Alk. phos. | | | | | |
| HBsAg | | | | | |
| Anti-HBs | | | | | |
| Anti-HTLV III | | | | | |
| Remarks/Note no. | | | | | |

Summarise any treatment with other products/clinical notes during this period: